慢性肝病患者接种新型冠状病毒冠疫苗研究进展

Research Progress of Novel Coronavirus Vac-cine in Patients with Chronic Liver Disease

慢性肝病患者发生严重新型冠状病毒疾病的风险和相关死亡率高于普通人群。欧洲肝病协会及美国肝病协会建议慢性肝病患者优先接种新型冠状病毒冠疫苗(以下简称新冠疫苗),然而,考虑到这些患者临床试验数据较少,疫苗的有效性以及疫苗相关不良事件的风险仍存在不确定性。在本综述中,我们总结了自新冠疫苗问世以来在慢性肝病患者中开展研究的相关结果。

Patients with chronic liver disease have a higher risk of severe novel coronavirus disease and asso-ciated mortality than the general population. The European Hepatology Association and the Ameri-can Hepatology Association recommend that patients with chronic liver disease be given priority for the novel coronavirus vaccine (COVID-19 vaccine). However, given the limited clinical trial data for these patients, there is still uncertainty about the effectiveness of the vaccine and the risk of vac-cine-related adverse events. In this review, we summarize the results of studies conducted in pa-tients with chronic liver disease since the introduction of COVID-19 vaccines.